Navigation Links
NORTHWEST BIO Announces Initiation of S&P Coverage, With Publication of First Company Stock Report
Date:10/25/2011

BETHESDA, Md., Oct. 25, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced initiation of Factual Stock Report coverage in conjunction with Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have corporate information disseminated to users of Standard & Poor's MarketScope Advisor, used by more than 100,000 investment advisors.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Starting with today's attached first Factual Stock Report, Standard and Poor's will make available a weekly updated Factual Stock Report on NORTHWEST BIO initiatives and strategy, as well as basic stock-related and financial information. Starting today, these Factual Stock Reports will be available through the NORTHWEST BIO website at www.nwbio.com and the MarketScope Advisor public website link at http://tinyurl.com/3hgsffh.

This first Report notes that, "When compared to other active immune therapy companies in the expanding cancer immune space, NWBO believes their DCVax technology is more effective, longer lasting, easier to administer, can be less costly, and can potentially apply to all patients with the target cancers, while certain other companies' treatments can only apply to a limited portion of the patient population and require screening of patients to determine which of them can be treated. In addition, NWBO has a deeper product pipeline, with multiple product lines and multiple target cancers already cleared for clinical trials by FDA. NWBO is unique in pursuing Europe in parallel with the US, for both its clinical trials and its manufacturing."

Linda Powers, CEO of NORTHWEST BIO, commented that, "It is important to our accelerating GBM brain cancer clinical trial program in both the US and Europe, that a financial organization of the significance of S&P is now following us and helping spread the word of our potential advantages as to cost, effectiveness, manufacturing, applicability to a larger patient population, and simplicity of delivery and administration. We welcome the increased attention as we work ever harder to bring the promise of DCVax to the global market."

The first step under this comprehensive S&P program was taken several weeks ago with the listing of NORTHWEST BIO in the Daily News section of S&P's Standard Corporation Records, a recognized manual for secondary trading in most states under their Blue Sky Laws.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products in both the US and Europe to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.  The Company has a broad platform technology for dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for metastatic ovarian cancer.  For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin Awarded Approved Vendor Status for American Medical Concepts Network of Hospitals in the Northwest U.S.
2. Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial
3. Northwestern Survey Finds FDA Predictability a Top Concern Among Medtech Firms; Europe Preferred for Product Approval
4. Northwestern Memorial Maintains Top Status in Nursing Hospital Renewed for Nurse Magnet®
5. Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study
6. Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond
7. Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing
8. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
9. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
10. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
11. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, RN, ... the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coalition ... muscular dystrophy, and funding for Duchenne research, participated in the April 25 U.S. ... Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott Conference Center in ...
(Date:4/29/2016)... ... 29, 2016 , ... The Society for Assisted Reproductive Technology ... required to report in vitro fertilization (IVF) delivery rates to both ... of assisted reproductive technologies in the United States. , This year, SART’s ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... The ... the workforce is aging – meaning that there is an urgent need for highly ... and interactive training solution, delivering a multi-pronged approach to train and retain care managers, ...
Breaking Medicine News(10 mins):